| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Alfacalcidol-D6 targets the vitamin D receptor (VDR), a nuclear receptor that mediates the biological effects of vitamin D. Activation of VDR regulates calcium and phosphate homeostasis, bone metabolism, and immune function. Alfacalcidol is a non-selective VDR activator.
|
|---|---|
| ln Vitro |
Alfacalcidol-D6 is the deuterium-labeled form of Alfacalcidol and is used as an analytical standard or tracer in research. Alfacalcidol is a non-selective VDR activator medication. The deuterated form is used in mass spectrometry-based studies for quantification and metabolic tracing.
|
| ln Vivo |
In vivo, Alfacalcidol acts as a VDR activator, regulating calcium and phosphate homeostasis and bone metabolism. Alfacalcidol-D6 is used in research as a tracer to study the pharmacokinetics and metabolism of Alfacalcidol. The deuterium labeling enables precise quantification by mass spectrometry.
|
| Enzyme Assay |
In vitro receptor binding assays for Alfacalcidol-D6 typically employ VDR preparations and measure binding affinity using radioligand binding or fluorescence-based assays. The deuterated form can be used as a tracer in competition binding experiments to determine the binding affinity of test compounds to VDR.
|
| Cell Assay |
In vitro cellular assays for Alfacalcidol-D6 involve treating VDR-expressing cell lines with varying concentrations of the compound. Readouts include assessment of VDR target gene expression (e.g., CYP24A1, osteocalcin) by qPCR, measurement of calcium metabolism markers, and evaluation of cell proliferation and differentiation.
|
| Animal Protocol |
In vivo animal studies for Alfacalcidol-D6 typically involve administration of the compound in rodent models to study vitamin D metabolism and pharmacokinetics. The deuterated form enables precise tracking of the compound and its metabolites by LC-MS/MS. Endpoints include measurement of calcium and phosphate levels, bone density, and metabolic profiling.
|
| ADME/Pharmacokinetics |
Alfacalcidol-D6 is the deuterium-labeled form of Alfacalcidol, used for pharmacokinetic and metabolic studies. Following administration, the compound is metabolized and tracked by LC-MS/MS. PK parameters including half-life, Cmax, and AUC are determined using the deuterated compound as an internal standard or tracer.
|
| Toxicity/Toxicokinetics |
Alfacalcidol-D6 is a research-grade compound for laboratory use only. As with all research chemicals, standard safety precautions should be observed during handling including appropriate PPE and work in a fume hood. The compound is not intended for human therapeutic use.
|
| References |
|
| Additional Infomation |
Alfacalcidol-D6 (CAS# 1641940-94-4) is the deuterium-labeled form of Alfacalcidol, a non-selective VDR activator medication. It is used as an analytical standard and tracer in research to study vitamin D metabolism and pharmacokinetics. Not for clinical use.
|
| Molecular Formula |
C27H44O2
|
|---|---|
| Molecular Weight |
406.6740
|
| Exact Mass |
406.371
|
| CAS # |
1641940-94-4
|
| Related CAS # |
Alfacalcidol;41294-56-8
|
| PubChem CID |
66577031
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
531.5±50.0 °C at 760 mmHg
|
| Flash Point |
222.6±24.7 °C
|
| Vapour Pressure |
0.0±3.2 mmHg at 25°C
|
| Index of Refraction |
1.534
|
| LogP |
8.31
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
643
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
[2H]C([2H])([2H])C(CCC[C@@H](C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C)C([2H])([2H])[2H]
|
| InChi Key |
OFHCOWSQAMBJIW-VLUFQIGVSA-N
|
| InChi Code |
InChI=1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1/i1D3,2D3
|
| Chemical Name |
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-7,7,7-trideuterio-6-(trideuteriomethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4590 mL | 12.2950 mL | 24.5900 mL | |
| 5 mM | 0.4918 mL | 2.4590 mL | 4.9180 mL | |
| 10 mM | 0.2459 mL | 1.2295 mL | 2.4590 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
